BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27703782)

  • 1. Ketamine: stimulating antidepressant treatment?
    Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
    BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
    Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 4. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
    Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
    Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High heterogeneity and low reliability in the diagnosis of major depression will impair the development of new drugs.
    Lieblich SM; Castle DJ; Pantelis C; Hopwood M; Young AH; Everall IP
    BJPsych Open; 2015 Oct; 1(2):e5-e7. PubMed ID: 27703745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
    Holt RIG; Gossage-Worrall R; Hind D; Bradburn MJ; McCrone P; Morris T; Edwardson C; Barnard K; Carey ME; Davies MJ; Dickens CM; Doherty Y; Etherington A; French P; Gaughran F; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Saxon D; Shiers D; Siddiqi N; Swaby EA; Waller G; Wright S
    Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between childhood maltreatment and inflammatory markers.
    Palmos AB; Watson S; Hughes T; Finkelmeyer A; McAllister-Williams RH; Ferrier N; Anderson IM; Nair R; Young AH; Strawbridge R; Cleare AJ; Chung R; Frissa S; Goodwin L; Hotopf M; Hatch SL; Wang H; Collier DA; Thuret S; Breen G; Powell TR
    BJPsych Open; 2019 Jan; 5(1):e3. PubMed ID: 30762500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
    J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple-therapy-resistant major depressive disorder: a clinically important concept.
    McAllister-Williams RH; Christmas DMB; Cleare AJ; Currie A; Gledhill J; Insole L; Malizia AL; McGeever M; Morriss R; Robinson LJ; Scott M; Stokes PRA; Talbot PS; Young AH
    Br J Psychiatry; 2018 May; 212(5):274-278. PubMed ID: 30517072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
    McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [No Abstract]   [Full Text] [Related]  

  • 13. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
    Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 15. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort.
    Asmar KE; Fève B; Colle R; Gressier F; Vievard A; Trabado S; Verstuyft C; Haffen E; Polosan M; Ferreri F; Falissard B; Chanson P; Becquemont L; Corruble E
    J Affect Disord; 2018 Dec; 241():22-28. PubMed ID: 30092445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficits in problematic internet use: meta-analysis of 40 studies.
    Ioannidis K; Hook R; Goudriaan AE; Vlies S; Fineberg NA; Grant JE; Chamberlain SR
    Br J Psychiatry; 2019 Nov; 215(5):639-646. PubMed ID: 30784392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESHRE guideline: endometriosis.
    Becker CM; Bokor A; Heikinheimo O; Horne A; Jansen F; Kiesel L; King K; Kvaskoff M; Nap A; Petersen K; Saridogan E; Tomassetti C; van Hanegem N; Vulliemoz N; Vermeulen N;
    Hum Reprod Open; 2022; 2022(2):hoac009. PubMed ID: 35350465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in dorsal and ventral posterior cingulate connectivity in APOE
    Kerestes R; Phal PM; Steward C; Moffat BA; Salinas S; Cox KL; Ellis KA; Cyarto EV; Ames D; Martins RN; Masters CL; Rowe CC; Sharman MJ; Salvado O; Szoeke C; Lai M; Lautenschlager NT; Desmond PM
    BJPsych Open; 2015 Oct; 1(2):139-148. PubMed ID: 27703739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder.
    Kusumi I; Arai Y; Okubo R; Honda M; Matsuda Y; Matsuda Y; Tochigi A; Takekita Y; Yamanaka H; Uemura K; Ito K; Tsuchiya K; Yamada J; Yoshimura B; Mitsui N; Matsubara S; Segawa T; Nishi N; Sugawara Y; Kako Y; Shinkawa I; Shinohara K; Konishi A; Iga J; Hashimoto N; Inomata S; Tsukamoto N; Ito H; Ito YM; Sato N
    BJPsych Open; 2018 Nov; 4(6):454-460. PubMed ID: 30450224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.